Searched for
GLP 1 THERAPY
'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugsDespite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges wi...- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- Margin pressure, slower growth outlook may cap upside for Sun Pharma stockSun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and...
- Why are Indians suddenly buying more vitamins after starting Ozempic-like weight loss drugs?Demand for vitamin and nutritional supplements is surging in India. This trend follows the increased availability of semaglutide-based weig...
- Eli Lilly’s obesity drug shows up to 30% weight loss in trialEli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This onc...
- Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in CanadaDr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Dr Reddy's and Nestle Health Science strengthen presence in diabetes, obesity nutrition spaceDr Reddy's teams up with Nestle Health Science to introduce Celevida GLP+, a specialized supplement crafted for those navigating the challe...
- Emcure eyes India growth, global deals amid strong demandEmcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...
- RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-SeptemberRPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company a...
- Dr Reddy’s Laboratories receives approval from Health Canada for its generic semaglutide injectionDr Reddy's Laboratories has achieved a significant milestone. Health Canada has approved its generic semaglutide injection. This makes Dr R...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- US Stocks | Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats upKailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....
Load More
